Hyperkalemia | Current Treatment | EU5 | 2016
Hyperkalemia is an important complication of chronic kidney disease (CKD) and end-stage renal disease (ESRD) with significant impacts on morbidity and mortality. Management of hyperkalemia is dependent on both patient symptoms and the elevation of serum potassium levels, and it typically involve potassium binders to control potassium levels in the body. These potassium binders have a significant side-effect profile; therefore, tolerable and effective treatments are needed. This content provides an in-depth examination of the different treatment and prescribing practices for hyperkalemia within Europe and offers insights for companies seeking to enter this market.
Related Market Assessment Reports
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is defined as a serum potassium level above 5.0 mEq/L. This report covers the management of chronic hyperkalemia through diuretic therapy, correcting metabolic acidosis when present,…
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS) is an umbrella term encompassing myocardial infarction and unstable angina. This report focuses on the secondary prevention of ACS (post-ACS), aimed at preventing…
